Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A brief course ...

Chronic cough in pulmonary fibrosis affects quality of life and correlates with mortality, yet objective measurement remains challenging. A wearable device combined with machine learning may offer a ...

Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted ...

The overall cough in idiopathic pulmonary fibrosis market is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging ...

Poor cough-specific quality of life (QOL) was independently associated with respiratory hospitalization, death, and lung transplantation in a large population of well-characterized patients with ...

A new analysis has found that coughing may signal trouble for patients with the lung-scarring disease known as idiopathic pulmonary fibrosis. The study, published in the journal Respirology, found ...

Pirfenidone, an oral antifibrotic, improves lung function and reduces acute pulmonary exacerbations in patients with grades 2-3 radiation induced lung injury.

Please provide your email address to receive an email when new articles are posted on . Patients receiving nintedanib vs. placebo had smaller changes in questionnaire scores signaling symptom ...

NEW HAVEN, Conn., March 8, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) ...

If you have a persistent cough and it does not seem to be going away no matter what you are doing, it could be worth visiting your GP as something more sinister could be going on. If you are talking ...

Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (TRVI) (NASDAQ: TRVI), a clinical-stage biopharmaceutical company ...